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Abstract
Background: Cardiac surgery is one of the most commonly performed surgical procedures worldwide with >
700,000 surgeries in 2006 in the US alone. Cardiac surgery results in a considerable exposure to physical and emotional
stress; stress-related disorders such as depression or post-traumatic stress disorder are the most common adverse
outcomes of cardiac surgery, seen in up to 20% of patients. Using information from a genome-wide association study
to characterize genetic effects on emotional memory, we recently identified a single nucleotide polymorphism of the
glucocorticoid receptor gene (the Bcll single nucleotide polymorphism) as a significant genetic risk factor for traumatic
memories from cardiac surgery and symptoms of post-traumaticstress disorder. The Bcll high-risk genotype (Bcll GG)
has a prevalence of 16.6% in patients undergoing cardiac surgery and is associated with increased glucocorticoid
receptor signaling under stress. Concomitant animal experiments have confirmed an essential role of glucocorticoid
receptor activation for traumatic memory formation during stressful experiences. Early cognitive behavioral intervention
has been shown to prevent stress-related disorders after heart surgery.
Methods/Design: The proposed study protocol is based on the above mentioned earlier findings from animal
experiments and preclinical studies in volunteers. Patients (n = 872) will be genotyped for the Bcll single nucleotide
polymorphism before surgery, which should result in 120 homozygous high-risk carriers of the Bcll GG allele and 240
randomly selected low-risk heterozygous or non-carriers of the single nucleotide polymorphism. All patients will then
undergo randomization to either cognitive behavioral intervention or a control intervention consisting of non-specific
general information about the role of stress in heart disease. The primary efficacy endpoint will be post-traumatic stress
levels at one year after surgery as determined by a standardized questionnaire that has been specifically validated in
patients after critical illness.
Discussion: The proposed randomized controlled trial intends to demonstrate that a preoperatively administered
minimal cognitive behavioral intervention targeted to homozygous carriers of the Bcll *G high-risk allele reduces
traumatic memories and post-traumatic stress disorder symptoms after heart surgery to a level seen in non-carriers of
the mutation, and thus improves the neuroemotional outcome of cardiac surgery.
Trial registration number: The trial will be registered at http://www.clinicaltrials.gov/ before commencing with the
study.
Keywords: Cognitive behavioral intervention, Genotyping, Glucocorticoid receptor, Personalized medicine,
Post-traumatic stress disorder, Prophylaxis, Single nucleotide polymorphism
* Correspondence: daniela.hauer@med.uni-muenchen.de
1Department of Anaesthesiology, Ludwig-Maximilians University, Munich
81377, Germany
Full list of author information is available at the end of the article
TRIALS
© 2013 Hauer et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Hauer et al. Trials 2013, 14:89
http://www.trialsjournal.com/content/14/1/89
Background
Cardiac surgery (CS) is one of the most frequent surgical
procedures worldwide with more than 700,000 cardio-
vascular procedures performed in 2006 in the US alone
[1]. Surgery and the subsequent intensive care unit
(ICU) therapy represent a considerable physical and
emotional stressor [2]. Whereas physical functioning
after CS improves over time, mental disorders as a result
of high perioperative stress such as chronic anxiety, de-
pression or post-traumatic stress disorder (PTSD) can
persist for months and years [2,3]. Up to 20% of patients
develop PTSD symptoms after CS [3]. Post-traumatic
stress in the presence of heart disease is linked to im-
paired health-related quality of life [4], reduced rate of
return to professional activities, increased health-care
utilization with considerable cost for health-care systems
[5] and a poor long-term cardiovascular prognosis [6].
However, although efficient treatments of PTSD exist,
little is known about preventing PTSD and other stress-
related disorders through evidence-based interventions
in critically ill patients undergoing CS or intensive care
therapy for other reasons. Therefore, targeted and cost-
effective interventions to improve the neuroemotional
outcome of extensive medical procedures are urgently
required [7].
In this randomized controlled trial, we intend to use
an innovative and personalized approach by identifying
carriers of a genetic risk factor (Bcll *G) for chronic
stress after CS and investigate whether a targeted
minimal behavioral intervention can counteract this gen-
etic vulnerability for PTSD symptoms and improve long-
term mental health.
The Bcll SNP of the glucocorticoid receptor influences
traumatic memories and PTSD stress symptoms in
patients undergoing cardiac surgery
The major risk factor for PTSD development in critically
ill patients is the presence of traumatic memories from
highly stressful experiences during ICU treatment [2,8].
Animal experiments performed by our research group
and others have repeatedly shown that the encoding of
traumatic experiences into emotional memory during
stress is facilitated by a stress-induced increase in gluco-
corticoid [9] and endocannabinoid signaling [10]. Using
information from a genome-wide association study to
characterize genetic effects on emotional memory in vol-
unteers (Figure 1), we have recently identified an in-
tronic SNP of the glucocorticoid receptor (GR) gene (the
Bcll SNP) in patients undergoing CS that is associated
with increased cortisol sensitivity of the GR and, thus,
enhanced glucocorticoid signaling under stress. The in-
creased cortisol sensitivity is seen in homozygous car-
riers of the Bcll *G allele, which has a prevalence of 14%
in the western European population [11] and 16.6% in
our patients undergoing CS [12]. Homozygous carriers
had a significantly increased risk for traumatic memories
and PTSD symptoms of chronic anxiety, pain, depres-
sion and impaired health-related quality of life after CS
Figure 1 Percentage of correctly recalled emotional pictures as compared to neutral pictures as a function of the Bcll single nucleotid
polymorphism of the glucocorticoid receptor gene in a genome-wide association study in 842 healthy individuals. Homozygous GG
carriers of the single nucleotide polymorphism recalled more emotional pictures than heterozygotes or non-carriers (left graph). The single
nucleotide polymorphism did not influence the recall of neutral pictures (right graph). Unpublished data provided by DQ.
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[12]. We very recently confirmed this finding in a sec-
ond study in an independent group of patients having
CS (unpublished, Figure 2). In combination, these well-
corroborated findings allow the preoperative identifica-
tion of patients at risk for PTSD symptoms after heart
surgery who could benefit from preventive interventions.
A cognitive behavioral intervention is effective in
preventing PTSD symptoms after intensive care therapy
Although counterintuitive, increased analgesia and sed-
ation of critically ill patients intended to prevent traumatic
experiences during ICU treatment has not been successful
in avoiding PTSD but has shown the opposite effect [13].
By contrast, a number of early interventions based on cog-
nitive behavioral intervention (CBI) have been effective in
improving the neuroemotional outcome of critical illness.
A study in patients having CS showed that preoperative
CBI (for example, explaining cardiac myths and miscon-
ceptions, detailing what to expect during the hospital stay
and subsequent recovery period) improved physical func-
tion and depression after surgery [14]. Early psychological
intervention in patients during ICU treatment by trained
psychologists resulted in a lower incidence of PTSD symp-
toms and a lower use of psychotropic medication during
follow-up [15]. The use of an intensive care diary, which
has comparable effects to CBI by changing how patients
think about their illness as they reread the story and build
an autobiographical memory, has also been effective in re-
ducing PTSD symptoms in patients after ICU therapy
[16]. A detailed explanation of the forthcoming events
during CS and ICU care will enhance the predictability of
the events and thereby reduce feelings of anxiety, helpless-
ness and life-threat. Evidence from both animal [17] and
human [18] research clearly indicates the detrimental ef-
fects of unpredictable stress, whereas anticipated stress ex-
hibits a milder impact on both psychological and physical
health. A preoperative CBI enhances predictability and
should therefore reduce the arousal during and directly
after surgery in the ICU and, consequently, the release of
excessive amounts of stress hormones and endocan-
nabinoids (ECs) [10] that contribute to the hypercon-
solidation of this potentially traumatic situation. Secondly,
prominent theoretical models of PTSD propose a dissoci-
ation between hyperconsolidated emotional memories and
poorly consolidated autobiographical context memories as
the root cause of intrusive memories in PTSD [19,20].
Therefore, a preventive CBI should provide detailed con-
text information prior to CS and shortly after CS, to locate
potential traumatic experiences in time and space. Al-
though previous studies have demonstrated that CBI has
benefits in improving the neuroemotional outcome of crit-
ical illness, none of the earlier investigations were aimed
specifically at patients with a genetically identified risk. By
contrast, we hypothesize that a preoperatively adminis-
tered minimal behavioral intervention targeted to carriers
of a genetic risk factor (Bcll GG) will reduce the risk for
development of PTSD to that of non-carriers of the allele.
This approach would be analogous to a prophylactic
immunization of individuals with a well-characterized risk
for an infectious disorder.
Figure 2 PTSD stress symptom scores according to Bcll genotype one week after discharge from the intensive care unit in a recent
confirmatory study in patients undergoing cardiac surgery (n = 95). *P = 0.02 compared to non-carriers (CC) of the SNP (one-way analysis of
variance with Holm-Sidak post-hoc test). Data represent means ± standard error of the mean (unpublished). PTSD, post-traumatic stress disorder.
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Figure 3 (See legend on next page.)
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Methods/Design
Intervention scheme/trial flow
The flow of events during the study is depicted in
Figure 3. After admission to the cardiac surgical ward,
patients eligible for the study will be asked whether they
are willing to participate. Patients will be told that if they
agree to take part in the study, they can expect the fol-
lowing to take place. They will undergo genetic testing
to identify a genetic risk within the stress hormone sys-
tem for chronic stress reactions after surgery. They will
then be randomized to either Intervention A, which pro-
vides specific information on postoperative procedures
and focuses on possible and unexpected stressful experi-
ences while in the ICU (the minimal behavioral inter-
vention), or to Intervention B, which gives more general
information about the role of stress during the peri-
operative period of CS.
After providing written informed consent, blood draw-
ing for genotyping and an evaluation of cognitive ability
will follow using the Mini Mental State Examination. Be-
fore randomization to either the intervention or the con-
trol group, the patients will be asked to complete a set of
validated questionnaires to evaluate PTSD stress symp-
toms, standardized disease-related traumatic memories,
depression, health-related quality of life, and current anx-
iety and pain. Randomization will be followed by the inter-
vention, performed by a psychologist. After surgery, the
patients will be admitted to the cardiovascular ICU. While
in the ICU (postoperative days 1 to 4), the patients will be
evaluated every 8 hours for sedation, delirium, pain and
anxiety. Treatment variables will be recorded. One week
after discharge from the ICU, the patients will be ap-
proached again by the study psychologist and asked to
complete the set of questionnaires on traumatic memories
from the ICU and post-traumatic stress intensity as well
as current anxiety and pain symptoms. Six and 12 months
after surgery, the patients will be interviewed by phone
and will be sent the set of questionnaires by mail.
The primary efficacy endpoint of the study is a reduc-
tion in post-traumatic stress measured by questionnaire
12 months after surgery. The primary hypothesis to be
tested is that this reduction is more pronounced for
high-risk homozygous Bcll SNP carriers compared to
the remaining patients.
Data collection
Collected data will include demographic factors, object-
ive indicators of myocardial function and severity of cor-
onary artery disease, current pharmacologic treatment
and dosage, cardiovascular risk factors, medical comor-
bidities, mental health history, episodes of high stress ex-
posures related to the current hospitalization, recurrent
symptoms of coronary heart disease, recurrent hospitali-
zations, compliance with medication, and type and in-
tensity of rehabilitation after CS.
Inclusion criteria
 Planned CS for coronary artery bypass grafting or
valvular heart disease using cardiopulmonary bypass
 age >18 years
 sufficient knowledge of the German language in
written and oral comprehension
 Western European origin (according to information
provided by the patient).
Exclusion criteria
 CS involving cardiocirculatory arrest under
controlled hypothermia
 unstable preoperative cardiovascular condition
requiring emergency procedures
 severe alcohol or drug abuse
 major pre-existing neurologic or psychiatric diseases
(for example, PTSD, major depressive/bipolar or
somatoform disorder)
 previous CS or treatment in an ICU with the
exception of brief stays in a coronary care unit
 cognitive impairment as determined by the nine-
item short version of the Mini Mental State
Examination
 chronic organ dysfunction (renal, liver or lung)
 severe comorbidities likely to cause death within one
year (for example, cancer)
 preoperative use of glucocorticoids (for example
because of rheumatism)
Selection of study population
The effect of the Bcll SNP on post-traumatic stress
and cortisol signaling has been characterized in patients
undergoing CS at our institution who fulfilled the
abovementioned criteria [12]. Patients satisfying the entry
criteria of our study are in every aspect comparable to
patients attending other European CS centers [21]. In
addition, our study is a multi-center study with two cen-
ters (Klinikum Grosshadern and Herzklinik Augustinum,
both in Munich). One can therefore assume that the re-
sults of our suggested study can be generalized.
(See figure on previous page.)
Figure 3 Flow chart showing the sequence of events and key points of decision making during the proposed study. Rounded rectangles
indicate tasks to be performed by medical personal (for example, the study physicians). Ovals represent the responsibilities of a study
psychologist and his or her team.
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Gender effects
The selected study population addresses possible gender
effects. In our previous study on the Bcll SNP effect in
patients undergoing CS, 30 of 126 patients studied were
female. Of these 30 women, 6 were homozygous and 24
were heterozygous or non-carriers of the SNP [12]. Even
in this small subgroup, female homozygous carriers had
significantly higher PTSD scores one week after dis-
charge from the ICU than female heterozygous non-
carriers (29.0 ±13.1 versus 16.2 ±6.7, P = 0.009). In the
proposed study, out of 180 patients intended to be in-
cluded (Figure 4), approximately 43 will be female. As-
suming that the effect of the homozygous Bcll *G SNP
and the gender distribution in both study samples is
identical, our study will be adequately powered to allow
the detection of gender-specific effects of the interven-
tion on post-traumatic stress one week after ICU dis-
charge and at one year (primary endpoint).
Figure 4 Flow chart depicting sample size estimation for the proposed study.
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Behavioral intervention to target traumatic memories and
post-traumatic stress after surgery and intensive care unit
treatment
The planned trauma-centered intervention will have an
informative and resource-oriented approach to activate
individual patient resources and cognitive (re)structuring
to prepare for the oncoming surgery and subsequent
ICU therapy. The major aim of the proposed interven-
tion is to create realistic expectations about potential
traumatic experiences that might occur, in order to ren-
der those experiences less surprising and hence reduce
the subjective feeling of helplessness and distress in the
patients. The intervention group will therefore be in-
formed that some of them may have uncomfortable and
potentially threatening experiences during the wake-up
phase from anesthesia after heart surgery and while in
the ICU. These potentially traumatic experiences could
include nightmares and sometimes hallucinations or
confusion, episodes of brief respiratory distress during
weaning from mechanical ventilation, feelings of anxiety
and some degree of pain from surgery. The study ther-
apist will point out that these phenomena almost never
occur during general anesthesia and heart surgery itself
but are sometimes seen during the wake-up phase in the
ICU after surgery. Participants will be told that these
aversive experiences occur despite the best efforts of the
therapeutic team in the ICU to avoid them by adminis-
tering sedative and analgesic drugs in adequate dosages
and the use of special techniques for extubation after
mechanical ventilation. The therapist will also stress that
these experiences usually do not indicate secondary
complications after heart surgery and are generally self-
limiting and of a temporary nature. The psychologist will
further explore resources of the patient (for example,
strategies that the patient had already successfully im-
plemented to reduce stress, their social support net-
works, and future hopes and perspectives) and will
encourage the patient to focus on these resources during
and after ICU therapy. This information will be given to
the patients in both written and oral form using simple
and easily understandable language. A second part of
the intervention is the provision of information about
the context at the time of awakening, to orientate the
patient in time and space directly after recovery from
anesthesia. Likewise, the connection between sensory
recollection about the potential traumatic experiences
and autobiographical memories should be encouraged.
Control intervention focusing on general aspects of
psychological stress
To achieve significant differences between the trauma-
focused ‘verum’ and the non-specific control interven-
tion, the approaches need to be sufficiently different to
avoid overlapping effects. The control intervention will
therefore strictly avoid addressing the topics of ‘trau-
matic experiences or memories’ or ‘post-traumatic stress’
and, in contrast to the intervention group, no detailed
information about the context of awakening will be
given. Instead, the control group will receive information
about the role of stress in heart disease and the possible
benefits resulting from the use of stress management
techniques in improving mental outcomes of CS. The
control intervention will address questions regarding dif-
ferences between normal daily stressors and pathological
stress with dangerous health consequences, and why
some individuals are more vulnerable to stress than
others. It will also describe the relationship between
pathological stress and an unhealthy lifestyle that results
in an increased risk for heart disease. Furthermore, ef-
fective methods to reduce stress will be described to the
patients. The patients will receive this information in
both oral and written form. As during the specific inter-
vention, all information will be given in a standardized
and easily understandable manner.
Additional treatments
All patients will be treated according to a strictly stan-
dardized protocol that has been used in all our previous
studies addressing traumatic memories and PTSD symp-
toms after CS [2,12,22]. The use of the sedative agent
propofol will be avoided, however, because a previous
animal study by our group has shown that this com-
pound may facilitate memory consolidation under stress
by interacting with the endocannabinoid system [23].
Likewise, the administration of stress doses of hydrocor-
tisone will also be avoided as hydrocortisone may have a
preventive effect on the development of PTSD symp-
toms after CS [24].
Outcome measures
Primary endpoint
We intend to use stress symptom scores determined by
the German version of the modified Post-Traumatic
Stress Symptom 10 questionnaire (PTSS-10) at one year
after CS as the primary endpoint. The PTSS-10 instru-
ment has been repeatedly validated in patients after ICU
treatment. In the first validation study performed by our
group, we used a double-blind interview technique
performed by psychiatrists, according to the Diagnostic
and Statistical Manual of Mental Disorders (DSM), third
edition criteria, to diagnose PTSD. This validation process
demonstrated a high internal consistency (Cronbach’s α =
0.93) and a high test-retest reliability (intraclass correlation
coefficient r = 0.89) of the instrument. The specificity and
sensitivity for diagnosis of PTSD after ICU treatment at a
cut-off value of 35 points of the questionnaire were 97.5%
and 77%, respectively [25]. The second and more recent
validation study was performed by an independent group
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and according to the newer DSM-IV criteria and demon-
strated that a PTSS-10 score of >20 one week after
weaning from mechanical ventilation reliably identified
patients who were diagnosed with PTSD three months
later: sensitivity 100%; specificity 76% with an area under
the receiver-operating characteristic curve of 0.91 [26].
The questionnaire has been used in multiple studies
investigating traumatic memories and post-traumatic
stress after ICU treatment by our [2,25,27-30] and other
[15,16,31-34] groups and has also been shown to be sensi-
tive to a pharmacologic intervention aimed at reducing
PTSD stress symptoms after CS and ICU therapy in gen-
eral, namely the use of hydrocortisone [24,33]. When used
in patients with coronary artery disease alone, without the
stressor of recent CS and at a single time point, the instru-
ment appears to considerably overestimate the incidence
of full syndromal PTSD when compared with an interview
technique (Structured Interview for DSM Disorders). But
even when used under conditions for which the instru-
ment has not been specifically validated, the PTSS-10 was
able to adequately quantify the intensity of disease-related
stress symptoms [34].
This instrument consists of two parts: Part A evaluates
four standardized categories of traumatic memory from
the ICU and Part B quantifies the presence and inten-
sities of 10 PTSD-related symptoms [25].
Traumatic memories A category of traumatic memory
as measured by Part A of the questionnaire is defined as
the patient’s subjective recollection of nightmares, re-
spiratory distress/dyspnea, feelings of anxiety/panic or
pain. When completing the questionnaire, the patient is
asked to answer each of these four items ‘yes’ or ‘no,’ in-
dependent of the number of occasions the adverse ex-
perience occurred. The number of ‘yeses’ answered by a
patient is termed the number of traumatic memories.
The intensity of traumatic memories is not specifically
evaluated by the questionnaire.
PTSD-related chronic stress symptoms The severity
and presence of PTSD symptoms is quantified by Part B
of the questionnaire and evaluates the presence and inten-
sity of ten PTSD-related stress symptoms: sleep disturb-
ance, nightmares, depression, hyperalertness, withdrawal
(emotional numbing and inability to care for others), gen-
eralized irritability, frequent changes in mood, guilt, fear
and avoidance reactions with regard to the ICU, and in-
creased muscle tension. When evaluating these symptoms,
the patients are asked to think back over the last few days
(‘presently - that means in the past few days - I suffer
from. . .’), and then asked if they had symptoms expressed
by statements such as: ‘Jumpiness, I am easily frightened
by sudden sounds or sudden movements’ (to evaluate
hyperalertness), ‘fear of places and situations which remind
me of the intensive care unit’ (to evaluate avoidance reac-
tions), or ‘a bad conscience, blame myself, have guilt feel-
ings’ (to evaluate guilt). Patients rated their symptoms
using a scale from 1 (never) to 7 (always). A summary
score can then be calculated that ranges from 10 to 70
points, with increasing scores indicating a higher preva-
lence and intensity of PTSD symptoms.
Traumatic memories and PTSS-10 stress symptom
scores will be evaluated before surgery, one week after
discharge from the ICU and at six months and one year
follow-up time points (Figure 3).
Secondary endpoints
Traumatic memories Traumatic memories will be quan-
tified by Part A of the modified PTSS-10 instrument (see
above).
PTSD symptom intensity as measured by the Post-
Traumatic Stress Diagnostic Scale The Post-Traumatic
Stress Diagnostic Scale is a brief but reliable self-report
measure of PTSD symptoms for use in both clinical and
research settings. This instrument will be used as a con-
firmatory measure of stress symptom intensity [35].
Depression We intend to use the German version of
the Beck Depression Inventory, which is regarded as a
standard instrument to evaluate depression in epide-
miologic studies and to rate depression in patients
with cardiovascular disorders. Depression will be quan-
tified preoperatively as well as six months and one year
after CS.
Delirium Delirium is a common complication in pa-
tients undergoing CS and is associated with negative
outcomes including cognitive decline, increased mortal-
ity and a higher of rate distress after ICU therapy, al-
though the association with PTSD development is not
entirely clear. The occurrence of delirium during ICU
treatment will be monitored using the Confusion As-
sessment Method instrument, which is recommended as
a standard tool for confusion assessment in the ICU (for
time points see Figure 3).
Sedation/agitation During ICU treatment, we intend to
quantify the degree of sedation versus the occurrence
of agitation by applying the widely used Richmond
Sedation Agitation Score, which classifies the patients
into three agitation categories: agitated, calm or sedated.
The instrument will be administered every 8 hours
while the patients are treated in the ICU (postoperative
days 1 to 4).
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Pain intensity We will ask the patients to indicate how
strong their current pain is by using a verbal rating scale
where 0 = no pain and 10 = the worst pain imaginable.
Pain intensity will be evaluated at every time point and
every 8 hours during ICU treatment.
Degree of anxiety We will ask the patients to indicate
how strong their current anxiety is by using a verbal rat-
ing scale where 0 = no anxiety and 10 = the highest anx-
iety imaginable.
Health-related quality of life Mental and physical qual-
ity of life including physical functioning will be evaluated
using the German version of the self-administered 36-
item Medical Outcomes Study Short Form Survey [36].
Endocannabinoids By measuring plasma ECs (see
Figure 3 for time points of these measurements), we
want to show that homozygous carriers of the Bcll *G
SNP with enhanced GR sensitivity have lower EC signal-
ing as a result of an increased inhibitory effect of gluco-
corticoids on the EC system and that this interaction
can be influenced by the targeted behavioral interven-
tion. This assumption results from a pilot trial that
demonstrated increased circulating concentrations of
ECs in CS patients with traumatic memories and PTSD
symptoms [37], a larger study in individuals with PTSD
from war and torture experiences [38] and decreased
perioperative plasma levels of ECs in CS patients who
developed depression after heart surgery [39]. Plasma con-
centrations of the ECs anandamide, 2-arachidonoylglycerol,
palmitoylethanolamide, N-arachidonoyldopamine, arachi-
donoylglycine, oleoylethanolamide, stearoylethanolamide,
2-arachidonoylglycerolether, N-oleoyldopamine, docosate-
traenoylethanolamide, dihomo-y-linoleoylethanolamide
and virodhamine will be determined using a method
based on high performance liquid chromatography-
tandem mass spectrometry as previously described [39].
Cortisol Morning plasma cortisol (8 am) will be deter-
mined using standard methods. Plasma cortisol will be
measured because, in our previous study, homozygous
carriers of the Bcll SNP had significantly lower morning
plasma cortisol levels [12]. Cortisol determination may
allow us to study the effect of the intervention on
plasma cortisol concentrations as a function of genotype.
Low plasma concentrations of cortisol have been de-
scribed in some but not all patients with PTSD and
stress doses of cortisol may reduce the intensity of PTSD
stress symptoms after CS [24].
Genotyping and biochemical analysis
All analyses will be performed from venous blood col-
lected in the appropriate tubes at the time points indi-
cated in Figure 3.
DNA preparation and genotyping
At least one day before surgery and after informed consent
by the patients, 10 ml of venous blood will be collected
and genomic DNA will be extracted using the QIAamp
DNA Blood Maxi Kit (Qiagen, Hilden, Germany). Infor-
mation on the Bcll polymorphic site of the GR was derived
from the database of single nucleotide polymorphisms
established by the National Center for Biotechnology
Information [40]. Genotyping will be done by high-
resolution melting DNA analysis with specific probe sets.
High-resolution melting represents a simple and low-cost
solution with a short turnaround time, which is important
for the preoperative genotyping intended in our study.
Genotype distributions will be checked for violations of
Hardy-Weinberg equilibrium.
Biomarkers of the systemic inflammation
C-reactive protein and interleukin-6 (IL-6) will be mea-
sured because patients with PTSD are known to have a
tendency for inflammation and a chronic inflammatory
response may mediate the increased cardiovascular risk
seen in these patients. C-reactive protein will be deter-
mined preoperatively and daily thereafter until ICU
discharge. For reasons of cost containment, IL-6 mea-
surements will be limited to three time points: preopera-
tively, postoperatively and one week after ICU discharge.
Statistical analyses
Sample size calculations
In several previous studies in CS patients, we assessed
post-traumatic stress using the PTSS-10 instrument that
will also be the primary outcome measure in this study.
Our preliminary work indicated an 8-point difference on
the PTSS-10 scale between homozygous Bcll *G carriers
as opposed to non-carriers [12]. This study also showed
that the PTSS-10 score did not significantly decrease until
six months after surgery. We may assume that the non-
trauma-focused control intervention does not change
post-traumatic stress levels in homozygous patients and
that the difference of 8 points in post-traumatic stress
scores between non-carriers and homozygous individuals
is clinically meaningful. This assumption is supported by
the recent study discussed in the section Primary endpoint
[26] that showed that even a relatively low PTSS-10 score
(>20) in patients one week after ICU therapy and weaning
from mechanical ventilation was highly predictive for the
later development of PTSD. Based on the results of our
pilot study [12], we make the following assumptions: first,
the mean PTSS-10 score one year after ICU discharge is
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18±8 (mean ±SD) for non-Bcll *G carriers and heterozy-
gous Bcll *G carriers and 25±8 for homozygous Bcll *G
carriers each under control intervention. Second, the
mean PTSS-10 score one year after ICU discharge is
18 ±8 for all patients under experimental intervention.
Both assumptions show a quantitative intervention-SNP
interaction. An overall sample size of 252 patients (84 per
SNP group) is needed assuming a type I error rate of 5%
and a type II error rate of 80% to detect a statistically sig-
nificant differential treatment effect between the genotype
groups. The sample size calculation was performed by
Nquery (Statistical Solutions Ltd.,4500 Airport Business
Park, Cork, Ireland). Further, experience from former
studies shows a perioperative mortality of 8% and a loss to
follow-up of approximately 20% of patients at the six-
month time point [2,12]. Adjustment for a drop-out rate
of 30% leads to a total of 120 required patients (120–0.3 ×
120 = 84) per SNP group. In our previous study in 126
Western European CS patients from our institution, 43%
were non-carriers of the Bcll *G, 43% were heterozygous
Bcll *G carriers and 14% were homozygous [12]. This
means that we will have to genetically screen approxi-
mately 872 patients to detect 120 homozygous individuals
eligible for randomization. Genetic screening will also re-
sult in the identification of approximately 376 non-carriers
and 376 heterozygous individuals. These patients will also
be randomly allocated to the control and the targeted
intervention group but, to reduce costs, only 120 individ-
uals with each genotype will be randomly selected by
choosing every third consecutive heterozygous or non-
carrier patient included in the study. Thus, we will have to
screen and genotype 872 patients to include 360 patients
into the final analyses (Figure 4).
Compliance rate and loss to follow-up
Previous studies from our group in the same study
population using comparable criteria for study inclusion
and the identical procedure for follow-up (phone calls
and questionnaires) yielded a high rate of compliance
and a low rate of loss to follow-up, which ranged be-
tween 20% [2] in 2003 and 16% in our most recent study
[12]. The 16% figure was used in the sample size calcula-
tion for the project.
Statistically, appropriate imputation techniques based
on the patient´s time course before dropping out will be
used to handle missing values as a result of patient
drop-out and recently suggested techniques for the pre-
vention of patient drop-out will be observed [41].
Randomization
The randomization ratio to the control and intervention
group is 1:1. Randomization will be performed by an
internet-based tool (Randoulette) [42].
Primary analysis
A two-factorial analysis of variance model will be used
that includes the binary factor ‘intervention’ and a tri-
nomial factor ‘genotype’. In a first step, an ‘interaction’
between both factors will be assessed. If this interaction
exists in a second step, differential treatment effects will
be tested between the three pairs of genotype groups.
The global alpha level is guaranteed since the closed
testing procedure will be invoked [43]. The primary data
analysis set is the intention-to-treat population, which
analyzes the data of the patients as they will have been
randomized [44].
Sensitivity analyses
The above analysis of variance model will be extended
to a linear mixed-effects (LME) model by considering
the longitudinal observations per patient (measurements
at four time points).
Secondary endpoints
As the secondary endpoints are collected at four different
times, we will use LME models (which respect the correl-
ation of the observations within a patient evolving over
time) and study the main and interaction effects of
the intervention and the SNP groups on the (possibly ad-
equately transformed) endpoints. Appropriate imputation
techniques will be used to handle missing values (results
of the LME model can help to impute the primary end-
point based on the patient’s time course before dropping
out, points missing in the longitudinal data can also be im-
puted) [45]. The analysis will be performed using the stat-
istical software environment R [46].
Ethical considerations
The study has been approved by the Ethical Committee of
the University of Munich (protocol# 137–11) and will be
performed in accordance with the 1964 World Medical
Association Declaration of Helsinki - Ethical Principles for
Medical Research Involving Human Subjects in its current
form from the 59th World Medical Association General
Assembly, Seoul, October 2008. Further, the study will be
conducted according to the Guideline for Good Clinical
Practice (International Conference on Harmonization,
Topic E 6 [R1]).
Due to the intended genetic testing, ethical aspects of
the trial require special considerations. The participants
will be informed that the research is performed solely
for the purpose of generating scientific knowledge about
genes or the genetic basis of disease and not to provide
participants or their families with specific information
about their genetic status or health, and at no time will
this information be divulged by the investigator, without
following specific guidelines provided. We will repeat-
edly stress that this study is for research purposes only
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and no individual results will be given back to the study
participant, go into medical records or find their way to
insurance companies or employers. This will include in-
formation from final results of the study, interim results
of the study and incidental findings. The record of par-
ticipation (including the consent form and research re-
sults) will never go into the medical record.
When giving informed consent the patients will re-
ceive the following information in both oral and written
form:
a) The informed consent is for research purposes only
and will not appear in the medical record.
b) Specific information resulting from genetic research
will not be available to participants and their
families.
c) Blood samples will eventually be shared with other
investigators (third parties). Shared samples will be
coded and remain anonymous to other investigators
and identification of patients from coded blood
samples will be impossible for third-party
researchers.
d) Blood samples will eventually be used for secondary
uses. In other words, research other than for what it
was collected. Secondary uses will only be done on
anonymized or anonymous samples.
e) A description of the special procedure required to
allow re-contacting of patients or relatives despite
strict confidence of genetic data.
f ) Two copies of the informed consent will exist. An
original copy will be filed in the research files and a
second copy will be for the participant.
Potential benefits to the participants
All participants in our study will receive detailed and
scientifically sound information regarding the relation-
ship between stress and coronary heart disease and how
to deal with possible stress effects after surgery. Thus,
participation in our study may be associated with benefit
for our patients, regardless of group assignment. Fur-
thermore, we will remain in contact with our patients by
phone and mail during the follow-up period of one year,
which makes the detection of adverse outcomes feasible.
Methods of protecting participant privacy, data and rights
Every possible care will be given to issues of confidenti-
ality. There will be no disclosure of study results to
participants, family members, insurance companies,
employers or other third parties without written per-
mission of the participant and approval by the Ethical
Committee of the University of Munich. Any shared
samples will be anonymized to the recipient.
All participating patients will receive a unique four-
digit identifier that will consist of a random combination
of letters and numbers. The identifier will not contain
letters or numbers derived from the patients name or
date of birth. The patients names and addresses and the
unique identifier will be stored in a coded file that will
be kept separate from other data files generated during
the study. All other files including those containing gen-
etic data will use the four-digit identifier.
After termination of the study, all study records except
genetic data will be stored in the central medical archive
of the University Hospital of Munich but kept separate
from medical records. A file linking genetic information
with names and addresses of the patients will then be
produced, a printout of this file will be stored by a no-
tary and the original electronic version of the file
destroyed. The notary will disclose the information
allowing patient identification under two conditions: a
written application by the original research team or the
treating physicians of the patient or relatives describing
the importance and possible benefit for patients or their
relatives, and approval by the local ethical committee.
Genetic information will only be disclosed to treating
physicians or researchers but never to insurance com-
panies, employers or other third parties.
Safety
Study participation for the participants will be associated
with minimal personal risk. Theoretically, the targeted
intervention focusing on traumatic experiences and
post-traumatic stress could result in a worsening of
symptoms as has been described in individuals after in-
voluntary emotional debriefing in the immediate after-
math of a highly traumatic event [47]. However, the fact
that our planned intervention uses a cognitive and infor-
mational approach and is performed before possible
emotional traumatization makes such negative effects
very unlikely. The risks associated with blood sampling
are also regarded as minimal. Nonetheless, the inci-
dences of adverse events and serious adverse events in
the treatment arms will be recorded by type and severity
and follow-up will be provided by repeated phone calls.
Discussion
Progress in the field of ICU therapy and medical proce-
dures such as CS has resulted in improvements in short-
and long-term survival rates in critically ill patients. This
progress is, however, met by an in increasingly older
population with increased life expectancy and multiple
comorbidities requiring extensive surgical procedures
and treatment in ICUs. By now, there are more than
10,000 critically ill patients treated in >1,500 ICUs on
any given day in Europe [48] and CS is one of the most
common surgical procedures performed worldwide. This
imbalance between demand, disease severity and the re-
quired efforts for cost containment makes it unlikely
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that further progress in surgical performance and life
support techniques in the ICU will result in meaningful
improvements in long-term outcomes of critically ill pa-
tients with heart disease requiring surgery. There is in-
creasing evidence that post-traumatic stress associated
with critical illness and ICU therapy has long-lasting
negative consequences on health-related quality of life,
cognitive and social functioning, health-care utilization
and even long-term mortality [2,49]. Published evidence
also shows that behavioral interventions are able to pre-
vent the development of post-traumatic stress symptoms
related to exposure to a range of different malignant
stressors including CS [14,50]. The overarching aim of
the proposed project is to demonstrate that a targeted,
CBI reduces the intensity of post-traumatic stress in pa-
tients undergoing CS and results in clinically meaningful
improvements in long-term outcomes six and twelve
months after surgery.
Time and staff resources of the therapeutic team car-
ing for CS patients are limited, however, and the timely
delivery of a targeted behavioral intervention to all CS
patients in a busy tertiary care hospital may exceed the
capacity of even large centers. Furthermore, the majority
of patients do not develop stress-related disorders after
CS and the intervention should therefore have no effect
on outcome in these individuals. A preoperative identifi-
cation of patients who might be particularly (or not at
all) susceptible to the intervention is therefore highly de-
sirable. The planned project addresses this issue and
tests the novel approach of preoperative genetic testing
to identify patients who might benefit from the interven-
tion (in the sense of individualized, personalized or
stratified medicine). If successful, the intervention could
be tailored to patients at risk and a great number of CS
patients might benefit with relatively little time invest-
ment. The added assessment of several biomarkers, both
established (for example, cortisol, cytokines and C-reactive
protein) and novel (for example, endocannabinoids), of-
fers the additional benefit of giving information on
intermediate biologic endpoint measures for traumatic
memories, post-traumatic stress and the atherothrom-
botic process in relation to genotype.
We believe that the unique combination of genetic
identification of patients at risk and testing the effect of
a targeted behavioral intervention according to genotype
on the neuroemotional outcome of CS is both sensible
and innovative.
Trial status
At the time of manuscript submission the study design
has been evaluated by independent international re-
viewers and is under consideration for possible support
by a major grant funder.
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